Lifecore Biomedical Inc Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Lifecore Biomedical Inc has an operating margin of -13.4%, meaning the company retains $-13 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -6.9% the prior year.
Lifecore Biomedical Inc's revenue grew a modest 0.5% year-over-year to $128.9M. This slow but positive growth earns a score of 30/100.
With a current ratio of 2.84, Lifecore Biomedical Inc holds $2.84 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.
While Lifecore Biomedical Inc generated -$206K in operating cash flow, capex of $13.4M consumed most of it, leaving -$13.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Lifecore Biomedical Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Lifecore Biomedical Inc generates $0.01 in operating cash flow (-$206K OCF vs -$38.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Lifecore Biomedical Inc earns $-0.8 in operating income for every $1 of interest expense (-$17.2M vs $21.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Lifecore Biomedical Inc (LFCR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Lifecore Biomedical Inc generated $128.9M in revenue in fiscal year 2025. This represents an increase of 0.5% from the prior year.
Lifecore Biomedical Inc's EBITDA was -$9.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 935.7% from the prior year.
Lifecore Biomedical Inc generated -$13.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 24.9% from the prior year.
Lifecore Biomedical Inc reported -$38.7M in net income in fiscal year 2025. This represents a decrease of 422.3% from the prior year.
Lifecore Biomedical Inc earned $-1.27 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 484.8% from the prior year.
Lifecore Biomedical Inc held $8.3M in cash against $130.4M in long-term debt as of fiscal year 2025.
Lifecore Biomedical Inc had 37M shares outstanding in fiscal year 2025. This represents an increase of 21.2% from the prior year.
Lifecore Biomedical Inc's gross margin was 31.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.4 percentage points from the prior year.
Lifecore Biomedical Inc's operating margin was -13.4% in fiscal year 2025, reflecting core business profitability. This is down 6.5 percentage points from the prior year.
Lifecore Biomedical Inc's net profit margin was -30.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 39.4 percentage points from the prior year.
Lifecore Biomedical Inc invested $8.3M in research and development in fiscal year 2025. This represents a decrease of 3.7% from the prior year.
Lifecore Biomedical Inc invested $13.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 27.1% from the prior year.
LFCR Income Statement
| Metric | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.1M-11.5% | $35.2M+8.0% | $32.6M+31.8% | $24.7M-30.8% | $35.7M+18.4% | $30.1M+23.0% | $24.5M-7.6% | $26.5M |
| Cost of Revenue | $23.3M-7.9% | $25.3M+17.8% | $21.5M+11.2% | $19.3M-18.9% | $23.8M+17.9% | $20.2M-7.3% | $21.8M+21.2% | $18.0M |
| Gross Profit | $7.8M-20.9% | $9.8M-11.2% | $11.1M+105.8% | $5.4M-54.7% | $11.9M+19.5% | $10.0M+265.0% | $2.7M-68.1% | $8.5M |
| R&D Expenses | $2.0M-4.0% | $2.0M+6.3% | $1.9M-12.0% | $2.2M+0.7% | $2.2M+3.4% | $2.1M-2.2% | $2.1M-3.9% | $2.2M |
| SG&A Expenses | $8.9M-11.9% | $10.1M-9.2% | $11.1M-24.8% | $14.8M+50.1% | $9.8M+5.4% | $9.3M+1.6% | $9.2M-10.5% | $10.3M |
| Operating Income | -$3.1M+66.0% | -$9.0M-360.9% | -$2.0M+83.1% | -$11.6M-1194.3% | -$895K+39.6% | -$1.5M+82.8% | -$8.6M-31.9% | -$6.5M |
| Interest Expense | $6.4M+16.5% | $5.5M | N/A | $5.4M+25.5% | $4.3M | N/A | N/A | $4.9M |
| Income Tax | $333K+4262.5% | -$8K-118.6% | $43K+272.0% | -$25K-111.5% | $217K+433.8% | -$65K-173.9% | $88K+25.7% | $70K |
| Net Income | -$10.0M+32.4% | -$14.8M-124.8% | -$6.6M+59.5% | -$16.2M-203.8% | $15.6M+9.9% | $14.2M+232.2% | -$10.8M+70.5% | -$36.5M |
| EPS (Diluted) | $-0.29+38.3% | $-0.47-88.0% | $-0.25+52.8% | $-0.53-226.2% | $0.42+7.7% | $0.39+211.4% | $-0.35+70.8% | $-1.20 |
LFCR Balance Sheet
| Metric | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $235.2M-1.0% | $237.7M-6.9% | $255.4M+3.5% | $246.8M+0.2% | $246.2M+0.2% | $245.8M+0.1% | $245.6M+3.8% | $236.7M |
| Current Assets | $83.9M-0.3% | $84.2M+2.9% | $81.9M+10.3% | $74.2M-2.6% | $76.2M-0.7% | $76.7M-7.4% | $82.8M-0.4% | $83.1M |
| Cash & Equivalents | $18.9M+248.1% | $5.4M-42.7% | $9.5M+71.3% | $5.5M+79.6% | $3.1M-4.6% | $3.2M-62.7% | $8.6M+192.9% | $3.0M |
| Inventory | $33.8M-2.3% | $34.6M-11.8% | $39.2M-5.8% | $41.6M+5.0% | $39.7M-4.3% | $41.4M-0.6% | $41.7M-0.8% | $42.0M |
| Accounts Receivable | N/A | N/A | $30.3M+20.5% | $25.1M | N/A | $29.0M | N/A | $31.0M |
| Goodwill | $13.9M0.0% | $13.9M0.0% | $13.9M0.0% | $13.9M0.0% | $13.9M0.0% | $13.9M0.0% | $13.9M0.0% | $13.9M |
| Total Liabilities | $245.7M+29.2% | $190.3M-2.7% | $195.6M-5.6% | $207.3M+11.0% | $186.8M-8.2% | $203.5M-7.1% | $219.1M+34.3% | $163.1M |
| Current Liabilities | $30.0M-3.7% | $31.1M-11.8% | $35.3M-12.9% | $40.5M+10.1% | $36.8M-8.6% | $40.3M+13.7% | $35.4M-5.3% | $37.4M |
| Long-Term Debt | $136.0M+8.8% | $124.9M+13.0% | $110.5M+4.7% | $105.5M+9.6% | $96.3M+4.6% | $92.1M+4.6% | $88.1M-11.0% | $98.9M |
| Total Equity | -$10.5M-572.7% | $2.2M-85.6% | $15.4M+492.2% | -$3.9M-122.3% | $17.7M+1144.6% | $1.4M+110.5% | -$13.6M-138.7% | $35.0M |
| Retained Earnings | -$218.1M-6.9% | -$204.1M-6.6% | -$191.5M-4.8% | -$182.8M-14.6% | -$159.4M+8.9% | -$175.1M+7.5% | -$189.3M-35.9% | -$139.3M |
LFCR Cash Flow Statement
| Metric | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.8M+46.8% | $1.2M+119.5% | -$6.1M-901.6% | -$613K+56.8% | -$1.4M-210.1% | $1.3M+115.5% | -$8.3M+29.0% | -$11.7M |
| Capital Expenditures | $1.7M-68.2% | $5.5M+123.6% | $2.4M-28.7% | $3.4M-46.3% | $6.4M+49.4% | $4.3M-15.7% | $5.1M-28.8% | $7.1M |
| Free Cash Flow | $25K+100.6% | -$4.3M+50.4% | -$8.6M-112.6% | -$4.0M+48.2% | -$7.8M-161.9% | -$3.0M+77.8% | -$13.4M+28.9% | -$18.8M |
| Investing Cash Flow | -$1.7M-212.5% | $1.5M+163.3% | -$2.4M+28.7% | -$3.4M+46.3% | -$6.4M-49.4% | -$4.3M+15.7% | -$5.1M-193.1% | $5.4M |
| Financing Cash Flow | -$1.4M+79.5% | -$6.8M-154.2% | $12.5M+1045.0% | $1.1M-85.7% | $7.6M+412.0% | -$2.4M-183.4% | $2.9M+21.5% | $2.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LFCR Financial Ratios
| Metric | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 25.0%-3.0pp | 28.0%-6.0pp | 34.0%+12.2pp | 21.8%-11.5pp | 33.3%+0.3pp | 33.0%+21.9pp | 11.1%-21.1pp | 32.2% |
| Operating Margin | -9.9%+15.8pp | -25.7%-19.7pp | -6.0%+40.9pp | -46.9%-44.4pp | -2.5%+2.4pp | -4.9%+30.2pp | -35.1%-10.5pp | -24.6% |
| Net Margin | -32.1%+9.9pp | -42.0%-21.8pp | -20.2%+45.5pp | -65.7%-109.5pp | 43.8%-3.4pp | 47.2%+91.0pp | -43.9%+93.7pp | -137.6% |
| Return on Equity | N/A | N/A | N/A | N/A | 88.4%-912.2pp | 1000.6% | N/A | N/A |
| Return on Assets | -4.3%+2.0pp | -6.2%-3.6pp | -2.6%+4.0pp | -6.6%-12.9pp | 6.3%+0.6pp | 5.8%+10.2pp | -4.4%+11.0pp | -15.4% |
| Current Ratio | 2.80+0.1 | 2.71+0.4 | 2.32+0.5 | 1.83-0.2 | 2.07+0.2 | 1.91-0.4 | 2.34+0.1 | 2.22 |
| Debt-to-Equity | -12.90-69.0 | 56.05+48.9 | 7.15+33.9 | -26.79-32.2 | 5.45-59.4 | 64.80+71.3 | -6.49-9.3 | 2.82 |
| FCF Margin | 0.1%+12.2pp | -12.1%+14.2pp | -26.4%-10.0pp | -16.3%+5.5pp | -21.8%-11.9pp | -9.9%+44.7pp | -54.6%+16.4pp | -70.9% |
Note: Shareholder equity is negative (-$861K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Lifecore Biomedical Inc's annual revenue?
Lifecore Biomedical Inc (LFCR) reported $128.9M in total revenue for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lifecore Biomedical Inc's revenue growing?
Lifecore Biomedical Inc (LFCR) revenue grew by 0.5% year-over-year, from $128.3M to $128.9M in fiscal year 2025.
Is Lifecore Biomedical Inc profitable?
No, Lifecore Biomedical Inc (LFCR) reported a net income of -$38.7M in fiscal year 2025, with a net profit margin of -30.0%.
What is Lifecore Biomedical Inc's earnings per share (EPS)?
Lifecore Biomedical Inc (LFCR) reported diluted earnings per share of $-1.27 for fiscal year 2025. This represents a -484.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Lifecore Biomedical Inc's EBITDA?
Lifecore Biomedical Inc (LFCR) had EBITDA of -$9.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Lifecore Biomedical Inc have?
As of fiscal year 2025, Lifecore Biomedical Inc (LFCR) had $8.3M in cash and equivalents against $130.4M in long-term debt.
What is Lifecore Biomedical Inc's gross margin?
Lifecore Biomedical Inc (LFCR) had a gross margin of 31.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Lifecore Biomedical Inc's operating margin?
Lifecore Biomedical Inc (LFCR) had an operating margin of -13.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Lifecore Biomedical Inc's net profit margin?
Lifecore Biomedical Inc (LFCR) had a net profit margin of -30.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Lifecore Biomedical Inc's free cash flow?
Lifecore Biomedical Inc (LFCR) generated -$13.6M in free cash flow during fiscal year 2025. This represents a 24.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lifecore Biomedical Inc's operating cash flow?
Lifecore Biomedical Inc (LFCR) generated -$206K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Lifecore Biomedical Inc's total assets?
Lifecore Biomedical Inc (LFCR) had $239.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Lifecore Biomedical Inc's capital expenditures?
Lifecore Biomedical Inc (LFCR) invested $13.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Lifecore Biomedical Inc spend on research and development?
Lifecore Biomedical Inc (LFCR) invested $8.3M in research and development during fiscal year 2025.
How many shares does Lifecore Biomedical Inc have outstanding?
Lifecore Biomedical Inc (LFCR) had 37M shares outstanding as of fiscal year 2025.
What is Lifecore Biomedical Inc's current ratio?
Lifecore Biomedical Inc (LFCR) had a current ratio of 2.84 as of fiscal year 2025, which is generally considered healthy.
What is Lifecore Biomedical Inc's debt-to-equity ratio?
Lifecore Biomedical Inc (LFCR) had a debt-to-equity ratio of -151.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lifecore Biomedical Inc's return on assets (ROA)?
Lifecore Biomedical Inc (LFCR) had a return on assets of -16.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Lifecore Biomedical Inc's cash runway?
Based on fiscal year 2025 data, Lifecore Biomedical Inc (LFCR) had $8.3M in cash against an annual operating cash burn of $206K. This gives an estimated cash runway of approximately 481 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Lifecore Biomedical Inc's debt-to-equity ratio negative or unusual?
Lifecore Biomedical Inc (LFCR) has negative shareholder equity of -$861K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Lifecore Biomedical Inc's Piotroski F-Score?
Lifecore Biomedical Inc (LFCR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lifecore Biomedical Inc's earnings high quality?
Lifecore Biomedical Inc (LFCR) has an earnings quality ratio of 0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Lifecore Biomedical Inc cover its interest payments?
Lifecore Biomedical Inc (LFCR) has an interest coverage ratio of -0.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Lifecore Biomedical Inc?
Lifecore Biomedical Inc (LFCR) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.